This is a dose-finding study using foscarnet for CMV prophylaxis after allogeneic bone marrow transplantation (BMT) in 20 high risk patients (unrelated donors, or T cell depleted, and/or advanced disease). Foscarnet was started on day ؉1 after BMT and continued until day ؉100. We explored four different dose levels, patients being entered at the lowest dose level until one patient experiences CMV-reactivation, identified as two 1-16 ). There was a dose effect of foscarnet on CMVAg-emia: respectively 4/5 patients (80%), 2/4 (50%), 3/5 (60%) and 1/6 (18%) at dose levels I, II, III, IV (P ‫؍‬ 0.1). CMV disease was seen in 3/9 (33%) at dose levels I, II and 0/11 at dose levels III, IV (P ‫؍‬ 0.07). The median number of CMV antigen-positive cells at diagnosis of CMV infection was different: 13 in dose levels I-II and two in dose levels III-IV (P ‫؍‬ 0.01). Increased creatininine was seen in 15 patients with a mean of 1.8 mg% (range 1.5-5.7) and was the cause of discontinuation in nine patients (45%). Renal toxicity was reversible in all nine patients. Overall actuarial TRM at 2 years was 31%: 47% for patients at dose levels I-II and 19% for patients at dose levels III-IV. In conclusion, foscarnet exhibits a dose-dependent prophylactic effect on CMVAg-emia, CMV disease and transplant-related mortality with acceptable and reversible renal toxicity. Bone Marrow Transplantation
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in allogeneic bone marrow transplant recipients (BMT). 1 Major risk factors for CMV pneumonia include: acute graft-versus-host disease (GVHD), allogeneic vs syngeneic or autologous transplantation, increasing patient age, use of total body irradiation and multiple agents in the pretransplant conditioning regimen. [2] [3] [4] There are two approaches for the prevention of CMV disease: the first is pre-emptive treatment of CMV infection, on the basis of CMVAg-emia [5] [6] [7] [8] positive blood CMV-PCR 9-12 or positive broncho-alveolar lavage. [13] [14] [15] The second option is CMV prophylaxis with agents such as gancyclovir 16, 17 or foscarnet. [18] [19] [20] Prophylaxis is probably necessary in patients at high risk of developing CMV infections: namely those receiving T cell-depleted grafts, and transplants from unrelated or mismatched donors. 18, 19 Prophylactic ganciclovir has been shown to be effective in preventing CMV disease in two randomized studies. 16, 17 However, it did not improve the outcome of the transplant, and survival was comparable in patients receiving placebo. This is due to the myelotoxicity and neutropenia in ganciclovir-treated patients. Foscarnet (trisodium phosphonoformate) is a synthetic antiviral drug with activity against all known human herpes viruses, including CMV. 20 It is registered in a number of countries for the treatment of CMV retinitis in AIDS patients. There is some experience of foscarnet treatment in CMV gastrointestinal disease in AIDS patients and it has also been used to treat CMV disease in transplant recipients. [21] [22] [23] An advantage of foscarnet is the lack of myelotoxicity and its activity against ganciclovir-resistant CMV. The most frequently reported adverse events in connection with foscarnet are changes in serum levels of calcium, magnesium and phosphate and decreased renal function. Prehydration with intravenous saline reduces the risk of nephrotoxicity. 24 In a previous study we have shown that foscarnet can prevent CMV infections in patients receiving T celldepleted grafts. 18 We are now reporting a dose-finding study for CMV prophylaxis, designed to test: (a) safety and tolerability of foscarnet; (b) efficacy in preventing CMV Bone Marrow Transplantation disease; and (c) influence of foscarnet prophylaxis on engraftment kinetics.
Patients and methods

Objectives and study design
This was a prospective, open, single center study. The primary objective was to find a dose of foscarnet which was safe and tolerable as CMV prophylaxis for BMT patients. The secondary objectives were to study the efficacy of foscarnet prophylaxis in preventing CMV disease and the influence on engraftment kinetics.
Four different dose levels were studied. Patients were entered at the lowest dose level until one patient experienced CMV-reactivation, as identified by two consecutive positive CMV-antigenemia tests. If none of the patients on the low-dose experienced severe toxicity, the subsequent patient was then entered on a higher dose level. At termination of the study none of 10 patients had developed CMV antigenemia, at a given dose.
Induction and maintenance treatment
Daily intravenous (i.v.) treatment from day ϩ1 until day ϩ30 was considered induction, whereas 5 days/week from day 31 until day ϩ100, was considered maintenance. The patients were followed daily for adverse events and clinical symptoms (Tables 1 and 2 ). Venous blood samples were obtained twice weekly from study start to day 30 and thereafter weekly up to day 100. Hematology and clinical chemistry were assessed in these samples for evidence of engraftment and safety of the prophylaxis. Weekly assessments of CMV IgG, IgM and pp65-antigenemia were performed. Samples for assessment of foscarnet peak and trough levels were obtained on three occasions during treatment in patients receiving the lowest dose of foscarnet, and saved frozen for later analysis. Samples for assessment of foscarnet levels were also obtained if drug toxicity was suspected.
Inclusion criteria for the study
These were (1) recipients of an allogeneic BMT; (2) CMV seropositivity (seropositivity being defined as Ͼ23 units by EIA); (3) high risk of CMV infection post transplant (patients receiving T cell-depleted grafts, and/or unrelated donor transplants and/or patients with advanced disease); (4) total/ionized calcium, magnesium and phosphorus concentrations within normal reference range; (5) age range 18 to 55 years; and (6) signed informed consent.
Exclusion criteria for the study
Exclusion criteria were (a) baseline estimated creatinine clearance Ͻ60 ml/min; (b) known hypersensitivity to foscarnet; (c) pregnant or nursing women; and (d) previous inclusion in this study.
Patient description
Patients clinical data are outlined in Table 1 .
Therapy and drug handling
Foscarnet: Solution for infusion 2.4% (24 mg/ml) from Astra Arcus AB, Sodertalje, Sweden.
Hydration: Before the first infusion of foscarnet, and concurrent with each subsequent foscarnet infusion, normal saline (0.9% NaCl) was infused.
Treatment plan
Initially patients received one infusion at a constant rate (over 1 h) of 30 mg foscarnet/kg every 12 h. If 10 patients tolerated foscarnet at 30 mg/kg twice a day and did not develop CMV antigenemia within day 100, the study would close. If one patient experienced CMVAgemia, he would complete the course, but the next patient would receive foscarnet at the high dose level. We explored four different dose levels ( Table 2 ). The 30 mg/kg and the 60 mg/kg infusions were given over 1 h and the 90 mg/kg dose over 2 h. Starting 1 h before the first administration and concurrent with each infusion, a normovolemic patient received 750 ml of normal saline. Dehydrated patients received additional fluid until fully rehydrated. If a peripheral vein was used for infusion, the foscarnet solution was diluted to 1.2% (12 mg/ml) by adding an equal volume of normal saline or 5% glucose.
If renal function deteriorated during treatment with foscarnet, dose adjustments were made as in Table 3 .
Toxicity
If one of three patients at a particular dose level experienced toxicity of grade 3 or above, believed to be due to foscarnet, three additional patients would be entered at this dose level. If two of six patients experienced severe toxicity, no further patients would be enrolled until data had been reviewed and there was a mutual agreement between the investigator and Astra that it was safe to continue the study. Table 1 Clinical data of patients who entered the trial according to the dose level of foscarnet prophylaxis 
Concomitant treatment
Treatment with ganciclovir was prohibited during the study period. Patients received prophylactic i.v. immunoglobulin 400 mg/kg once a week during the study period. Patients also received prophylactic pefloxacin and fluconazole p.o. Patients received conditioning therapy before transplantation, including total body irradiation (750-990 rads) and cyclophosphamide 60 mg/kg ϫ 2.
Statistical analysis
The Fisher test was used for 2 ϫ 2 tables; the rank sum Mann-Whitney test was used for differences between continuous variables. Kaplan-Meier plots were used to calculate the actuarial transplant-related mortality (TRM).
Results
Compliance, duration of treatment, treatment discontinuation
Thirteen of 20 patients stopped study medication prematurely: (Table 4 ) two cases stopped foscarnet because of deterioration of their underlying disease (both patients were in group IV); six patients stopped foscarnet because of CMV reactivation, (three in group I, one in group II, two in group III). Five patients stopped the drug because of renal impairment: of these, two discontinued the drug temporarily and then recommenced, whereas three did not start foscarnet again owing to early death (n ϭ 1) or medical decision (n ϭ 2) (one because of renal impairment due to myeloma, and one restarted the protocol, but only 3 days/week, due to persisting renal problems). We calculated the actual dose of foscarnet which could be administered, compared with the planned dose and expressed it as a percentage (%) of the planned dose: InducBone Marrow Transplantation tion dose (day 1-30), the median percentage of the planned dose for the induction period was 94% (79-103%) for dose level I (30 mg/kg ϫ 2/day), and 84.9% (64-96%) for dose level II, III, IV (60 mg/kg ϫ 2/day) ( Figure 1 ). Maintenance dose (day 31-100), the median percentage of foscarnet administered was as follows: 88% (65-103%), 84% (64-97%), 71% (61-79%), 60% (31-84%) for dose I, II, III and IV respectively (Figure 1 ).
Concomitant treatment
Potential nephrotoxic drugs administered during the study period were as follows: amikacin and/or gentamycin, and/or nethilmicin and/or tobramycin in 17/20 patients, vancomycin and/or teicoplanin in 16/20 patients, amphotericin B in 12/20 patients, ceftazidime in 17/20 patients, cyclosporin in 14/20 patients.
Safety
The 20 patients enrolled in this study were all eligible for analysis of safety. Baseline characteristics of the patients are described on Table 1 . Other parameters of safety included.
Clinical examinations
Blood pressure and pulse rate: The following definitions are valid: hypotension ϭ systolic blood pressure р90 mm Hg; hypertension ϭ diastolic blood pressure Ͼ90 mm Hg on two consecutive occasions; tachycardia ϭ pulse Ͼ100 bpm on more than two occasions. There were two patients with treatment-dependent hypotension and one patient with hypertension; tachycardia was recorded in one patient with hypotension and in an additional nine patients.
Body weight: Eighteen of 20 patients experienced weight reduction, ranging from 1.5% to 20% of initial body weight, and in one patient this did not change during the study period; in one patient it increased to 10% at treatment termination in association with abnormal renal function.
Body temperature: Seven of 20 patients had у38°C on two occasions or more. In one of these fever was also reported as an adverse event, in two patients it occurred in association with bacterial infection and in one patient fever appeared closely associated with graft-versus-host disease. 
Laboratory tests
Liver and renal function, electrolytes, albumin, creatinine, hematology variables and urinalyses were continuously followed in all patients.
Liver function tests: Treatment-related abnormalities in one or more liver function tests including alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (ALP) and bilirubin were recorded in 19 (95%) of patients. Increases in ALAT and AST and decreases in ALP were the most frequently recorded abnormalities; the only reported adverse events were increased bilirubins in two patients (Table 5) . One of these died before the bilirubin value was followed up, and in the other patients the value had not normalized at follow-up.
Renal function tests:
Treatment-related increases in serum levels of creatinine and BUN were recorded in 15 patients (75%). Increased BUN was also recorded in another three patients. In only two patients was there no treatment-related deterioration in renal function. An increased serum creatinine was reported as an adverse event in 10 of the 15 patients where creatinine levels were raised above the upper reference limit. There was one additional report of a raised serum creatinine, but in this patient the creatinine level was not increased above the upper reference limit.
Electrolytes: All patients experienced treatment-related abnormalities in one or more of the electrolytes. Most frequently seen were hyperphosphatemia, hypomagnesemia, hyponatremia and hypokalemia. Hyperkalemia and hypo- calcemias possibly/probably related to foscarnet sodium, whereas the hypernatremia was assessed as unlikely to be related to foscarnet treatment. Renal dysfunction was concomitantly reported in these patients.
Albumin: Seven patients experienced reductions below the lower reference limit, probably due to the underlying disease, but considered to be of negligible significance.
Creatinine kinase: Increased levels were not recorded for any patient.
Hematology: There were no reports of adverse hematological events due to foscarnet. All patients experienced treatment-related decreased platelet counts, leukocyte counts and hemoglobin levels due to the underlying hematological disease and the conditioning therapy.
Urinalysis: Urine samples from 12/20 patients were analyzed for presence of albumin, glucose and erythrocytes using qualitative methods. Erythrocytes appeared in the urine of seven patients, albumin and glucose in one, albumin only in one and glucose in three patients.
Adverse events
Nine patients experienced serious adverse events which constituted a definite hazard or handicap including death, permanent or severe disability or inpatient hospitalization. Five patients had reversible renal failure with complete recovery, one patient had hematuria (complete recovery), one hypertension and cerebral hemorrhage, and two general physical impairment. The following adverse events were reported in more than one patient: anxiety, depression, vomiting, hematemesis, melena, ulcerative stomatitis, BUN increase, glycosuria, hyperkalemia, hypernatremia, hypocalcemia, weight increase, hypertriglyceridemia, hypertension, cardiac failure, vasodilatation, coughing, pulmonary edema, respiratory insufficiency, anuria, pain.
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Treatment discontinuation: Thirteen of 20 patients stopped the study medication prematurely, two because of deterioration in the underlying disease and six because of CMV reactivation. Five patients had renal impairment: four recovered their renal function, and one died of acute GVHD within 15 days of discontinuation of foscarnet. Seven patients completed the planned prophylaxis up to day 100 post BMT without reactivation of CMV.
Efficacy
CMV antigenemia: There were no patients with CMV antigenemia during the induction period (0-30) and 10 with CMV antigenemia in the maintenance period (days 31-100), at a median interval of 53 days (range 33-89) (Table  4) , with a median of 10 CMV antigen positive cells (range 1-16). We saw CMV antigenemia in 4/5 patients at dose levels I and 2/4 patients at dose levels II, 3/5 patients at dose levels III and 1/6 patients at dose level IV. Of these, four in group I, II and three in group III, IV occurred during treatment with foscarnet and two and one, respectively, after foscarnet was discontinued ( Figure 2 ).
CMV disease: CMV disease occurred in 3/8 patients (37%) at dose level I and II, and 0/12 at dose levels III and IV (P ϭ 0.07) (Figure 2 ).
Engraftment:
There was no influence on white blood cells engraftment: in the first group the median of the day of engraftment was 16 (11) (12) (13) (14) (15) (16) (17) (18) , in the second group 22 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) , in the third 16 (14) (15) (16) (17) (18) (19) (20) (21) , in the fourth 15 (13) (14) (15) (16) (17) (18) .
Transplant-related mortality (TRM):
In groups I, II 4/9 patients died on days ϩ344 (hepatitis), ϩ107 (CMV pneumonia), ϩ80 (acute GVHD) and ϩ53 (multiorgan failure). Three of these had developed CMV antigenemia. In groups III, IV, 2/11 patients died on days ϩ95 (aGVHD) and ϩ30 (aGVHD). The overall actuarial 1 year TRM is 31%: it is 47% vs 18% for patients in group I, II and III, IV respectively (P ϭ 0.1) (Figure 3 ). 
Discussion
This study suggests that (1) foscarnet causes dose-related reversible renal toxicity; (2) foscarnet can be used from day ϩ1 after allogeneic BMT without interfering with hemopoietic engraftment; (3) there is a dose-related prophylactic effect of foscarnet on CMV antigenemia and CMV disease with associated reduction of transplant-related mortality.
Adverse events are of primary concern when drugs are used prophylactically, and renal toxicity has been reported with the use of foscarnet. 18 Renal toxicity was seen in this study and was dose dependent. Because adjustment of the foscarnet dose was allowed, according to creatinine levels, the actual dose of foscarnet was reduced when creatinine levels increased: at dose level 1 the actual dose received in the first 30 days was 93% and at dose levels III, IV it was 84%. The actual dose administered between day ϩ31 and day ϩ100 was 88%, 84%, 71% and 60% for dose levels I, II, III, IV, respectively. It should be noted that nephrotoxic agents were used together with foscarnet in all patients, including cyclosporin and amphotericin B. Five patients had renal failure at a median interval from BMT of 33 days (range ϩ7-ϩ49). There was complete recovery of renal function in four patients, whereas one died of acute GVHD with a creatinine level of 1.9 mg%. One patient had anuria due to urethral bleeding and severe hemorrhagic cystitis: he recovered after dialysis.
There was no hematologic toxicity at all four dose levels tested, and this is of great importance in the setting of bone marrow transplantation. This suggests that foscarnet can be used from the very early phases of engraftment, and perhaps also before the transplant, making it possibly the drug of choice for the early post-transplant period, when ganciclovir cannot be administered. Following these results we commenced a pilot study in patients undergoing unrelated transplantation, starting foscarnet from day Ϫ7, with encouraging results. 25 As to the efficacy of foscarnet prophylaxis, there was no reactivation of CMV within 30 days of BMT, but 10 patients reactivated between day ϩ30 and day ϩ100. This indicates that there are two distinct periods and the critical one is the latter. We were able to show a dose effect with six reactivations in nine patients (66%) at dose levels I and II, and four reactivations in 11 patients (36%) at dose levels III and IV. CMV disease was seen in 3/9 patients (33%) at dose levels I and II and 0/11 at dose levels III and IV. The median number of CMV antigen positive cells was also different: 13 at dose levels I and II and two at dose levels III-IV (P ϭ 0.01).
Therefore, increasing the dose of foscarnet reduces the incidence and severity of CMV antigenemia and this has an impact on transplant-related mortality: TRM was 47% at dose levels I and II and 18% at dose levels III and IV. If one considers that the eligibility for this study called for either T cell depletion, or an unrelated donor, or advanced disease and that eight patients had at least two of these adverse factors, an overall actuarial TRM of 31% at 1 year is low, and the 18% mortality at dose levels III and IV is very encouraging. Only one patient died of CMV pneumonitis at dose levels I and II. We are currently using dose level III, with a reduction during the induction phase (day ϩ1/ϩ30): 30 mg/kg twice daily from day Ϫ7 to day ϩ30 and 90 mg/kg/day 5 days a week from day ϩ31 to day ϩ100.
25
In conclusion, this study shows that foscarnet can be used successfully, with appropriate dosing, in the prevention of CMV antigenemia after allogeneic BMT. The dose of foscarnet administered has an impact on CMV reactivation. It remains to be determined whether improved survival will also result, when foscarnet prophylaxis is compared to controls not receiving the agent.
